June 12, 2018 (Alpharetta, Ga.) Dilon Devices has appointed Avihai Lachman as Vice President of Research and Development, leading the company’s effort in expanding the use of Radio Frequency (RF) Spectroscopy for new clinical applications and disease sites.
Lachman joins Dune after more than a decade of developing radio frequency technologies. He spent the past 18 years with Gilat Satellite Networks developing digital communication algorithms for satellite modems and tracking antenna systems mainly for the in-flight connectivity market. Lachman brings experience in mechanical design for RF modules and a proven track record of moving products from the concept phase to mass production. Lachman earned both Bachelor and Master of Science Degrees in Electrical Engineering from Ben-Gurion University in Beersheba, Israel.
“Adding Avihai to the leadership team is another milestone for Dune,” says Dilon CEO Lori Chmura. “Avihai’s proven track record as a leader in the field of RF will strengthen our expertise and focus to expand our proprietary RF spectroscopy platform into new devices and oncology markets.”
“To improve outcomes for cancer patients, none of us can afford to sit still, and Dune has demonstrated this with its first product, MarginProbe, that uses RF Spectroscopy to identify microscopic residual cancer,” says Lachman. “I am honored to work alongside the Dune team to extend the application of RF Spectroscopy beyond breast cancer surgery and expand the company’s surgical oncology portfolio.”
The MarginProbe identifies microscopic residual cancer in real time, during breast conserving surgery for breast cancer. It enables surgeons to remove suspicious tissue during the surgery reducing the incidence of positive margins which would require a second operation. MarginProbe is currently being used by surgeons worldwide and has been shown to reduce re-excision rates for lumpectomy surgery by 50 – 79 percent. The technology is based on two well known principles; first, the reflection of electromagnetic fields depends on the underlying electrical properties of the tissue they interact with and second, the electrical properties of cancerous tissue are different from those of normal tissue.
As the first step in expanding the platform, Dune is developing a revolutionary device which incorporates its proprietary RF spectroscopy onto a core needle biopsy device to enable the radiologist to receive real time data from the tip of the needle. The project is fully funded by the extremely competitive Horizon 2020 grant awarded to Dune in 2016.
About Dilon Devices
Imagine not having to wonder, did we get it all?
At Dilon Devices, we believe in reducing the anxiety that waiting for pathology results places on a patient and their families. Our solutions, which are developed on a first-of-its kind RF Spectroscopy platform can differentiate cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question, “did we get it all?”
Vice President, Healthcare
Write2Market for Dilon Devices
+1 (404) 414-4240